Traders Purchase Large Volume of Teladoc Health Call Options (NYSE:TDOC)

Teladoc Health, Inc. (NYSE:TDOC) was the target of some unusual options trading on Wednesday. Investors bought 36,233 call options on the stock. This is an increase of approximately 43% compared to the average volume of 25,327 call options.

Insiders Place Their Bets

In related news, insider Adam C. Vandervoort sold 5,720 shares of the firm’s stock in a transaction dated Tuesday, December 2nd. The stock was sold at an average price of $7.49, for a total transaction of $42,842.80. Following the completion of the sale, the insider directly owned 80,732 shares of the company’s stock, valued at approximately $604,682.68. This trade represents a 6.62% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Charles Divita III sold 17,138 shares of the stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $7.63, for a total transaction of $130,762.94. Following the transaction, the chief executive officer directly owned 201,036 shares of the company’s stock, valued at approximately $1,533,904.68. This trade represents a 7.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 33,288 shares of company stock valued at $251,684. 0.58% of the stock is owned by company insiders.

Institutional Investors Weigh In On Teladoc Health

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Y Intercept Hong Kong Ltd purchased a new position in shares of Teladoc Health during the second quarter worth about $2,722,000. Farther Finance Advisors LLC lifted its holdings in shares of Teladoc Health by 424.5% in the 2nd quarter. Farther Finance Advisors LLC now owns 9,960 shares of the health services provider’s stock valued at $87,000 after purchasing an additional 8,061 shares during the last quarter. Ameritas Advisory Services LLC acquired a new stake in shares of Teladoc Health in the 2nd quarter valued at about $78,000. Wealth Management Associates Inc. purchased a new position in Teladoc Health during the 2nd quarter worth approximately $509,000. Finally, Strs Ohio purchased a new position in Teladoc Health during the 1st quarter worth approximately $349,000. 76.82% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have commented on TDOC shares. Weiss Ratings restated a “sell (e+)” rating on shares of Teladoc Health in a research note on Monday, December 29th. BMO Capital Markets initiated coverage on Teladoc Health in a research note on Thursday, November 13th. They set a “market perform” rating and a $8.00 target price on the stock. Bank of America lowered their target price on Teladoc Health from $9.00 to $8.00 and set a “neutral” rating for the company in a report on Tuesday, November 25th. Barclays assumed coverage on Teladoc Health in a research report on Tuesday, December 9th. They issued an “equal weight” rating and a $8.50 target price for the company. Finally, Evercore ISI reduced their price target on shares of Teladoc Health from $9.00 to $8.00 and set an “in-line” rating on the stock in a research report on Thursday, October 30th. Five research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Teladoc Health has a consensus rating of “Hold” and a consensus price target of $9.50.

Teladoc Health Trading Up 1.5%

TDOC opened at $6.16 on Thursday. The business has a fifty day moving average price of $7.18 and a 200 day moving average price of $7.71. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.70 and a quick ratio of 2.60. Teladoc Health has a 12 month low of $6.03 and a 12 month high of $15.21. The stock has a market capitalization of $1.09 billion, a price-to-earnings ratio of -4.81 and a beta of 2.04.

Teladoc Health (NYSE:TDOC) last posted its quarterly earnings results on Wednesday, October 29th. The health services provider reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.05. The company had revenue of $626.44 million for the quarter, compared to analyst estimates of $625.66 million. Teladoc Health had a negative return on equity of 10.59% and a negative net margin of 8.84%.Teladoc Health’s revenue for the quarter was down 2.2% compared to the same quarter last year. During the same quarter last year, the company earned ($0.19) EPS. Teladoc Health has set its Q4 2025 guidance at -0.250–0.100 EPS. Sell-side analysts expect that Teladoc Health will post -1.16 earnings per share for the current fiscal year.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.